RT Ashlee Vance (@ashleevance)I happened to be at @neuralink last night when Starship went boom. And so was @elonmusk until well past midnight PT. He was in three-hour+ long meeting when the explosion happened. Meeting ended. I assume that's when he learned about it. And then . . . he went back to work. ...

RT Tesla Owners Silicon Valley (@teslaownersSV)"The next Neuralink product is BlindSight which will enable people who have lost both eyes or have no eye sight to see."Elon Muskhttps://t.co/uv8ExkuGrU ...

Company Highlight - Neuralink 首位人体植入者发布了暖心消息 [1]

"The next Neuralink product is BlindSight which will enable people who have lost both eyes or have no eye sight to see."Elon Muskhttps://t.co/uv8ExkuGrU ...

RT Ryan Tanaka (@RyanTanaka3)Neuralink is working on solving these brain/ spine problems:- Blindness- Paralysis- Hearing loss- Tinnitus- Memory loss- Depression- Insomnia- Extreme pain- Seizures- Anxiety- Addiction- Strokes- Brain damage- Neck pain- Back pain ...

Investment Rating - The industry investment rating is "Positive" and maintained [8] Core Viewpoints - The successful completion of China's first invasive brain-computer interface (BCI) clinical trial marks the country as the second globally to enter this stage, following the United States [2][5] - The stock price of Regenative Medicine (RGC) surged by 283.12% to $60 on June 16, indicating strong market interest in BCI technology [2][5] - The BCI medical application market is projected to reach between $40 billion and $145 billion globally by 2030 to 2040, with China's market expected to grow from 3.2 billion yuan in 2024 to over 5.5 billion yuan by 2027 [5] Summary by Sections Event Description - The first invasive BCI clinical trial in China was conducted by the Chinese Academy of Sciences and Fudan University, demonstrating significant advancements in BCI technology [5] - The trial involved a male subject who regained control over a computer touchpad after 2-3 weeks of training, showcasing the potential of BCI technology for improving the quality of life for patients with spinal cord injuries and amputations [5] Market Dynamics - The rapid progress in overseas BCI technology has garnered significant market attention, with companies like Neuralink and Regenative Medicine leading advancements [5] - The BCI market is expected to expand rapidly, driven by technological breakthroughs in medical rehabilitation [5] Investment Opportunities - Three main investment lines are suggested: 1. Domestic mapping of advanced overseas invasive BCI industry chains 2. Non-invasive BCI products in consumer scenarios 3. Downstream application targets related to BCI technology [5]

Core Viewpoint - The article discusses the remarkable stock performance of Regencell, a Chinese company listed in the US, which has seen its stock price increase by 600 times in 2025, reaching a market capitalization of over $38.5 billion (approximately 270 billion RMB) [4][5]. Company Overview - Regencell is an early-stage Chinese medicine biotechnology company focused on developing standardized liquid herbal formulas for treating ADHD and ASD patients [5]. - The company was founded in 2014 in Hong Kong and currently operates with a small team of only 12 employees [5]. - Despite its soaring stock price, Regencell has reported zero revenue since its inception and has been operating at a loss, with net losses of $6.062 million and $4.363 million for the fiscal years 2023 and 2024, respectively [5][10]. Stock Performance - Regencell's stock price surged dramatically, with a notable increase of 283% on June 16, 2025, and a pre-market rise of 64% the following day, reaching a closing price of $78 [4]. - The company's market capitalization is compared to major Chinese companies, being about 10% of Alibaba's market cap and 90% of Pop Mart's [4]. - The stock's liquidity was previously low, with only 11.2% of shares in circulation, prompting a stock split to enhance liquidity [4]. Founder Background - The founder, Regencell's CEO, graduated from UC Berkeley and has a background in investment banking, having completed over $4 billion in transactions [7]. - The founder's personal experience with ADHD and ASD, along with the influence of his father's traditional Chinese medicine practice, inspired the establishment of Regencell [8]. Market Dynamics - The surge in Regencell's stock price is attributed to the broader excitement around brain-computer interface (BCI) technologies, rather than its core business in traditional Chinese medicine [10][11]. - Recent advancements in BCI technology, including FDA-approved clinical trials for a new neural modulation chip, have fueled investor interest in related stocks [11][12]. - The article notes that the stock's performance appears disconnected from the company's actual business fundamentals, highlighting a speculative trend in the market [13].

BREAKING: Rob Greiner, the sixth human implanted with Neuralink’s Telepathy chip, can play video games by thinking, moving the cursor with his thoughts. https://t.co/sJeH44YdfS ...

Group 1 - The brain-computer interface (BCI) concept has seen a significant surge, with related stocks experiencing substantial gains, including Beiyikang reaching a "30CM" limit up and Aipeng Medical hitting a "20CM" limit up [1][2] - The first humanoid robot full industry chain exhibition in China is set to take place on June 20 in Hangzhou, featuring Tesla and Yushu, showcasing advanced technologies including bionic drive and BCI [1][4] - The BCI market in China is projected to reach 5.58 billion yuan by 2027, indicating rapid growth and commercialization potential [1][6] Group 2 - Chinese concept stocks related to BCI have seen a significant rise, with companies like Aipeng Medical and Nanjing Panda Electronics experiencing limit up and substantial gains [2][3] - Nanjing Panda Electronics is developing a multimodal human-computer interaction system based on BCI technology, targeting applications in medical rehabilitation and smart wearables [3] - The market for BCI applications is expected to reach hundreds of billions of dollars, driven by various favorable developments and advancements in technology [4][6] Group 3 - The global BCI market is estimated to reach between 4 billion to 145 billion dollars in the medical field by 2030-2040, with non-invasive products currently leading commercialization [5][6] - The global BCI market size reached 1.98 billion dollars in 2023, with expectations to exceed 6 billion dollars by 2028, reflecting a compound annual growth rate of 25.22% [6]

Group 1 - The core belief is that non-invasive brain-computer interface (BCI) technology will have a profound impact on humanity, with Qiang Brain Technology emerging as a leader in the global BCI field, ranking second in financing scale [1][3] - The two common technical routes in the BCI field are invasive and non-invasive, with invasive solutions being more suitable for severe medical conditions but posing safety risks, while non-invasive technology is advancing to capture brain activity signals more accurately [3][4] - According to a Morgan Stanley report, the market value of BCIs in the medical field in the U.S. alone is estimated at $400 billion, indicating significant industry potential [3] Group 2 - Qiang Brain Technology, originating from Harvard University's innovation lab, focuses on solving real-life problems rather than solely on self-developed technologies, targeting areas such as rehabilitation and health for various groups including disabled individuals and children with attention deficits [4] - The non-invasive BCI technology can transform educational scenarios by personalizing learning experiences and integrating BCI technology into AI course designs, promoting interdisciplinary development [4] - In 2024, Qiang Brain Technology plans to launch a dexterous hand product, entering the embodied intelligence field, and has become a supplier for humanoid robot dexterous hands due to its superior sensitivity and responsiveness compared to traditional robotic solutions [4][5]